In vivo ERK1/2 reporter predictively models response and resistance to combined BRAF and MEK inhibitors in melanoma.

Sanchez IM, Purwin TJ, Chervoneva I, Erkes DA, Nguyen MQ, Davies MA, Nathanson KL, Kemper K, Peeper DS, Aplin AE. In vivo ERK1/2 reporter predictively models response and resistance to combined BRAF and MEK inhibitors in melanoma. Mol Cancer Ther. 2019 Jul 03.

View in: PubMed